Department of Cardiovascular Surgery, Istanbul University, Istanbul-Türkiye.
Kantosspital Aarau Vascular and Endovascular Surgery Clinic, Aarau-Switzerland.
Ulus Travma Acil Cerrahi Derg. 2024 Aug;30(8):525-530. doi: 10.14744/tjtes.2024.74411.
Intimal hyperplasia is a normal adaptive feature of arteries in response to injuries, which include invasive vascular interventions. Its development limits the long-term success of bypass grafts. Various pharmacological agents have been successfully employed in experimental models to reduce the degree of intimal hyperplasia. In our study, we investigated the efficacy of dexamethasone in reducing intimal hyperplasia in rat abdominal aortas after partial transection and primary repair.
In this study, 20 Wistar Albino rats were randomly selected and divided into four groups to compare the effects of low- and high-dose dexamethasone on intima and media thickness compared to the control. Group A (n=5) was the control group, where only skin incision and laparotomy were performed. For Group B (n=5), a median laparotomy was performed, the abdominal aorta was partially transected, and repaired with an 8.0 prolene suture. Doses of 0.1 mg/kg and 0.2 mg/kg dexamethasone were administered in Group C (n=5) and Group D (n=5), respectively. After two weeks, all rats were euthanized, and the repaired abdominal aortas were excised and examined histopathologically. Intima and media thicknesses were measured using the 'Olympus AnalySIS 5' program (Olympus Corporation, Japan) after digital photos were taken.
Based on the measurements, we demonstrated that after transection and repair of the abdominal aorta, the intima/media ratio was not significantly different between the low-dose dexamethasone and non-dexamethasone groups. The intima/media ratio was significantly lower in the high-dose dexamethasone group than in the non-dexamethasone and low-dose dexamethasone groups.
After vascular interventions, dexamethasone treatment may reduce intimal hyperplasia and increase patency by providing vascular remodeling.
内膜增生是动脉对损伤的一种正常适应性特征,包括有创的血管介入。其发展限制了旁路移植物的长期成功。各种药理学制剂已成功地应用于实验模型中,以减少内膜增生的程度。在我们的研究中,我们研究了地塞米松在减少大鼠腹主动脉部分横断和初次修复后的内膜增生中的疗效。
在这项研究中,随机选择了 20 只 Wistar 白化大鼠,并将其分为四组,以比较低剂量和高剂量地塞米松对内膜和中膜厚度的影响,并与对照组进行比较。A 组(n=5)为对照组,仅进行皮肤切口和剖腹术。B 组(n=5)进行正中剖腹术,部分横断腹主动脉,并用 8.0 prolene 缝线修复。C 组(n=5)和 D 组(n=5)分别给予 0.1mg/kg 和 0.2mg/kg 的地塞米松。两周后,所有大鼠被安乐死,切除修复后的腹主动脉,并进行组织病理学检查。拍照后,使用“Olympus AnalySIS 5”程序(日本 Olympus 公司)测量内膜和中膜的厚度。
根据测量结果,我们表明,在腹主动脉横断和修复后,低剂量地塞米松和非地塞米松组之间的内膜/中膜比值没有显著差异。高剂量地塞米松组的内膜/中膜比值明显低于非地塞米松和低剂量地塞米松组。
血管介入后,地塞米松治疗可能通过提供血管重塑来减少内膜增生并增加通畅率。